Overview
Biopharmaceutical firm's Q4 operating income and pretax profit beat analyst expectations
Net loss for Q4 was $50.7 mln, up from last year
Company has $439 mln cash, providing runway into 2029
Outlook
Cullinan plans to share initial CLN-978 data in Q2 2026 for SLE and RA
Company expects repeat dosing data for CLN-978 in RA by Q3 2026
Cullinan anticipates CLN-049 Phase 1 update for AML in H2 2026
Result Drivers
CLN-978 PROGRESS - Strong enrollment momentum for CLN-978 positions Cullinan to deliver data for a potential best-in-class CD19 T cell engager in autoimmune diseases by Q2 2026
ZIPALERTINIB MILESTONE - Completion of rolling NDA submission for zipalertinib marks progress in collaboration with Taiho, with top-line results expected by year-end 2026
CASH RUNWAY - Cullinan reported $439 mln in cash and investments, providing operational runway into 2029
Company press release: ID:nGNX8KxCrM
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income | -$50.71 mln | ||
Q4 Operating Income | Beat | -$55.26 mln | -$56.48 mln (11 Analysts) |
Q4 Pretax Profit | Beat | -$50.71 mln | -$51.45 mln (11 Analysts) |
Q4 Operating Expenses | $55.26 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Cullinan Therapeutics Inc is $31.50, about 105.7% above its March 9 closing price of $15.31
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments